By Nick Spittal, Chief Operations Officer, Velocity Clinical Research Most sponsors and CROs talk about slow sites, hard-to-find patients, and protocol complexity putting their studies at risk. Those issues are all real, and they frequently share the same underlying cause: the disparate operating model used across individual study sites. In my experience, study risk often … Read more
When a large-scale vaccine trial needed to move fast, Velocity delivered — not once, but twice, across two continents. In the United States, Velocity was the sole site network selected to enroll participants for the trial. Across just 10 sites, the team enrolled 1,000 participants in 3.5 weeks. That’s the kind of speed that only … Read more
Advarra’s announcement of a new risk‑based AI governance framework features Raghu Punnamraju, CTO of Velocity Clinical Research, underscoring Velocity’s role in advancing responsible AI in clinical trials. Velocity is a founding member of the Council for Responsible Use of AI in Clinical Trials, a cross‑industry group convened by Advarra that brings together leaders from biopharma, … Read more
At Velocity Clinical Research Albuquerque, clinical research is being delivered in a way that reflects the community it serves. Led by Dr. Sara Friedman, a Principal Investigator with a background in OB/GYN, the Albuquerque site is a female-led team focused on women’s health and vaccines. Their work sits at the intersection of scientific rigor and … Read more
Douglas Logan, MD, recently retired from Velocity, but his presence is as big as ever. Talk to our U.S. PIs about their route into research, or their experience at Velocity, and his name is likely to come up. For Matthew Wenker, MD, that story goes back nearly two decades. When he first stepped into clinical … Read more
For much of her early career, Abbie Youkilis, MD focused on changing healthcare from the outside in. Having begun as a pre-med student at Duke, she pivoted into public policy, earning a master’s degree from Harvard and working in Washington on health policy and aging issues. But over time, she found herself drawn back to … Read more
There is a logic to the way William Cromwell, MD speaks about cardiometabolic risk — if this, then that. But you never feel as though it would come at the expense of the person sitting opposite him. Over the past 35 years of specialty practice, research, teaching, and publishing, his emphasis has remained the same. … Read more
By Evelyne Newton, Business Development Europe at Velocity Clinical Research Next week I will join industry leaders to explore one of the most pressing questions facing sites across Europe: how can clinical trial sites diversify therapeutic areas sustainably without compromising quality? In a competitive and fast-moving environment, diversification is often framed as a necessary growth … Read more
By Andrew Reina, Chief Revenue Officer Clinical research is at an inflection point. Sponsors and CROs are being asked to deliver trials that start faster, enrol more predictably, and generate data that stands up to increasing regulatory and commercial scrutiny. In that environment, long-standing approaches to site selection, which are often shaped by reputation, relationships, … Read more
When you first meet Fritz Raiser, DO, you could be forgiven for thinking he was on holiday. There’s a quiet ease about him, a calm confidence that feels almost out of place for someone who spends half his week in a busy emergency room and his days leading clinical trials. Warm and approachable, Dr. Raiser … Read more